



ShareSoc

UK Individual Shareholders Society

20 Wenlock Road
London - N1 7GU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

**CREO – Creo Medical****34.00p** $\uparrow$ 0.00 0%

EMS: 5k

Healthcare · Speculative · Small Cap · High Flyer

Market Cap

Enterprise Value

Revenue

Position in Market

£122.83m

£105.53m

£29.23m

781st / 1,701

Quality

Value

Momentum

StockRank™

▲ 66

14

▲ 66

▲ 45

1m 3m YTD **1y** 3y All**Momentum**

Relative Strength (%)	
1m	+9.03% ●
3m	+0.980% ●
6m	+35.1% ●
1y	-36.1% ●
Volume Change (%)	
10d / 3m	+182% ●
Price vs... (%)	
52w High	-33.3% ●
50d MA	+2.26% ●
200d MA	+18.8% ●

Growth & Value

12m Forecast Rolling		Industry	Market
PE Ratio (f)	n/a		
PEG Ratio (f)	n/a		
EPS Growth (f)	n/a		
Dividend Yield (f)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	1.78		
Price to Tang. Book	2.88		
Price to Free Cashflow	n/a		
Price to Sales	4.20		
EV to EBITDA	n/a		

Shareholder Activity

	Buy / Hold / Sell
Institutions	
Directors	
Community	

Screens Passed: 0 Long

1 Short

CREO qualifies for **Altman Z-Score Screen** (Short Selling)[View Screen](#) [View Checklists](#)**Quality**

	Industry	Market
Return on Capital	-36.8%	
Return on Equity	-38.6%	
Operating Margin	-96.57%	

Financial Summary

Year End 31st Dec		2017	2018	2019	2020	2021	2022	TTM	2023E	2024E	CAGR / Avg
Total Revenue	£m	0.000	0.000	0.013	9.43	25.2	27.2	29.2	32.7	40.6	
Operating Profit	£m	-8.90	-17.7	-18.9	-23.5	-29.9	-30.8	-28.2			
Net Profit	£m	-7.77	-14.8	-15.9	-20.3	-24.6	-26.9	-25.1	-19.1	-11.4	
EPS Reported	p	-9.27	-15.8	-12.6	-12.6	-14.4	-14.3	-11.4			
EPS Normalised	p	-9.27	-15.8	-12.6	-12.5	-14.4	-14.3	-11.4	-5.80	-3.22	
EPS Growth	%										
PE Ratio	x										
PEG											
Profitability											
Operating Margin	%			-140.129	-249	-119	-113	-96.6			-23.435%
ROA	%		-45.0	-23.1	-22.5	-25.5		-28.5			
ROCE	%	-60.8	-36.7	-22.7	-31.5	-37.0	-53.2	-36.8			-40.3%
ROE	%		-47.5	-24.4	-27.9	-36.1	-43.9	-38.6			-36.0%
Cashflow											
Op. Cashflow ps	p	-8.26	-15.2	-9.42	-10.1	-15.3	-13.3	-10.5			
Capex ps	p	0.268	1.48	0.888	0.357	3.59	1.74	0.792			45.4%
Free Cashflow ps	p	-8.53	-16.7	-10.3	-10.4	-18.9	-15.1	-11.3			
Dividends											
Ex-date: 17 Oct / Paid: 17 Oct											
Dividend ps	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Dividend Growth	%										
Dividend Yield	%							0.000	0.000	0.000	
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	13.7	44.6	81.0	45.1	43.5	13.1	26.5			-0.880%
Working Capital	£m	14.3	46.9	81.0	41.4	41.4	16.2	37.2			2.53%

Health Trend (F-Score)

6/9

**Bankruptcy Risk (Z2-Score)**

3.09

**Earnings Manipulation Risk (M-Score)**

Low

Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	13.3	21.5	13.3
Net Gearing %	-25.07	-40.52	-25.1
Cash / Assets %	29.88		29.9
Liquidity (ttm)			
Curr. Ratio			4.13 ●
Quick Ratio			3.45 ●
Interest Cov.			100.00 ●
Efficiency (ttm)			
Asset Turnover			0.36
Recs Turnover			4.14
Stock Turnover			1.87

Year End 31st Dec		2017	2018	2019	2020	2021	2022	TTM	2023E	2024E	CAGR / Avg
Net Debt	£m	-13.7	-44.2	-80.3	-32.7	-33.0	-1.41	-17.3			
Net Fixed Assets	£m	0.340	0.926	1.30	4.46	12.2	14.0	13.3			110%
Book Value	£m	14.7	47.7	82.7	62.8	73.3	49.4	69.0			27.5%
Average Shares	m	84	94	126	162	170	188	232			18%
Book Value ps	p	17.5	38.2	53.0	38.4	39.1	26.3	19.7			8.46%

FINANCIAL BRIEF: For the six months ended 30 June 2023, Creo Medical Group PLC revenues increased 15% to £15.7M. Net loss... [See more](#)

Recent History

Latest interim period vs. prior period		Industry	Market
Sales Growth	15.12%		
EPS Growth	n/a		
3yr Compound Annual Growth Rate		Industry	Market
Sales CAGR	1,163.48%		
EPS CAGR	n/a		
DPS CAGR	n/a		

Graphical History






Revenue

Net Income

Normalised EPS

PE Ratio Range

Dividend Yield Range



Analyst Forecasts


Price Target: 99.50p (192.65% above Price)	31st Dec 2023			31st Dec 2024		
	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Est. Long Term Growth Rate:						
Consensus Estimate	-19.13m	-5.8	0.0	-11.40m	-3.2	0.0
1m Change		0.0			0.0	
3m Change	-385.00k	+0.7		-30.00k	+0.1	

Analyst Consensus

3 brokers



EPS 2023 / 2024



Profile Summary

Creo Medical Group plc is a medical device company. The Company is focused on the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. It is engaged in research, development and distribution of electrosurgical medical devices rela... [Read more](#)

Directors

Craig Gulliford CEO

Christopher Hancock CTO

Richard Rees CFO

David Woods EDR

Charles Spicer NEC (52)

John Bradshaw NID

Ivonne Cantu NID


Last Annual	Dec 31, 2022
Last Interim	Jun 30, 2023
Incorporated	Sep 12, 2016
Public Since	Dec 9, 2016
Ex-Dividend Date	Oct 17, 2023
Payment Date	Oct 17, 2023
No. of Employees	279
No. of Shareholders	n/a

Sector	Healthcare
Industry	Healthcare Equipment & Supplies
Index	FTSE AIM All Share Index, AIM Health Care Index
Exchange	LSE AIM Market
Asset Category	Common Stock
Shares in Issue	361,251,418
Free Float	288,612,329 (79.89%)
Eligible for	✓ ISAs ✓ SIPPs

Address	Unit 2 Beaufort Park,, Beaufort Park Way, CHEPSTOW, NP16 5UH, United Kingdom
Web	https://creomedical.com/
Phone	+441291606005
Auditors	PricewaterhouseCoopers LLP

CREO Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread
34.00p	34,012	33.50p - 34.50p	0.00p - 0.00p	294bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
↓ 0.00 0%	572,549	34.00p - 34.00p	19.00p - 51.00p	1.044



Latest News for CREO

Yesterday 9:16 am

Announcement

Creo Medical Group - Change of Nominated Adviser and Joint Broker

Thu, Oct 12, 2023

Announcement

RCS - Creo Medical Group - Investor Presentation

Sep 12, 2023

News

BRIEF-Creo Medical Group Posts H1 Gross Profit 7.5 Million Stg

Sep 12, 2023

Announcement

Creo Medical Group - Half-year Report

Sep 5, 2023

Announcement

Creo Medical Group - Notice of Results

Similar to CREO

Compare

☐	Apex Biotechnology High Flyer	85
☐	OK Biotech Co High Flyer	61
☐	Medimaging Integrated Solution High Flyer	46
☐	Daiken Medical Co High Flyer	83
☐	Meditera Tibbi Malzeme Sanayi ve Ti... Neutral	39
☐	Onward Medical NV Sucker Stock	6
☐	Semler Scientific Super Stock	94
☐	Zimvie Turnaround	80

Upcoming Events for CREO

Thursday, October 19th 2023

Creo Medical Group PLC Company Overview Presentation

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2023 © Stockopedia 2023, Refinitiv, Share Data Services.

- **Important Information:** To use Stockopedia, you must accept our Terms of Use, Privacy and Disclaimer & FSG. All financial services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.
- This communication cannot substitute for professional investment advice or independent factual verification. Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.
- Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. Stockopedia looks for stocks that meet certain pre-defined criteria and presents the results to help users perform their own research. For more Important Information please refer to the Disclaimer section in the Stockopedia website.
- This communication may contain general Financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
- Company data is derived from data provided by Refinitiv
- Each company on Stockopedia is evaluated on the basis of hundreds of fundamental and technical metrics that measure a company's Quality, Value, Growth, and Momentum.
- QVM StockRanks™:
 - This measure equally blends the Quality, Value and Momentum ranks into a core metric, the StockRank.
- QualityRank™:
 - The QualityRank is based on a composite of carefully selected company factors based on the latest academic research into understanding 'Quality'. The factors used are inspired by the writings of Warren Buffett, Joseph Piotroski, Edward Altman and Messod Beneish, as well as recent papers from Robert Novy-Marx of the University of Chicago and National Bureau of Economic Research.
 - Each company in the market is ranked from 1 to 100 for each of these Quality Factors and a composite score is calculated as a weighted average of all these values. The QualityRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- ValueRank™:
 - Our ValueRank is based on a composite of the following Value factors: Price to Book Value ; Price to Earnings ; Price to Free Cash Flow ; Dividend Yield % ; Price to Sales ; Earnings Yield %

- Consistent with the value investing philosophy, we use historic ratios for each of these metrics, rather than factoring in analyst forecasts. Each company in the market is ranked from 1 to 100 for each of these value ratios and a composite score is calculated as the weighted average of all valid values. The ValueRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- MomentumRank™:
 - The MomentumRank is based on a composite of the following Price and Estimate Momentum Factors.
 - Price Momentum Factors:
 - Proximity of current share price to the 52 week high ; 50 day vs 200 day moving averages ; 1 year Relative Strength of the share price vs the market ; 6 Month Relative Strength of the share price vs the market.
 - Earnings Momentum Factors:
 - EPS estimate upgrades within the last one month for next financial year ; EPS estimate upgrades within the last three months for this financial year ; EPS surprise percentage based on the latest reported financials ; Scaled earnings surprise based on the standard deviation of the original Consensus forecast ; Consensus broker recommendation upgrade over the last month
 - Each company in the market is ranked from 1 to 100 for each of these momentum ratios and a composite score is calculated as a weighted average of all valid values. The MomentumRank is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
 - When a company has no broker coverage we cannot calculate earnings momentum. As a result the Momentum Rank is calculated using price momentum factors alone.